Christopher Twelves, MD

Twelves says a common misconception in breast cancer is that with the current flood of new treatments in HER2-positive breast cancer, the issue of breast cancer overall has been largely addressed.

Twelves said historically, chemotherapy combinations have been created utilizing empirical evidence, which he says is not a sound rationale for the combinations. He adds that due to certain biological properties of eribulin mesylate, the treatment warrants further investigation as a combination therapy.

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology, University of Leeds, discusses a pooled analysis of eribulin for the treatment of patients with breast cancer.